Assembly Biosciences, Inc.
ASMBHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeAssembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Valued at $531.3M, ASMB is a small-cap name in its sector. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Market Cap
$531.3M
Beta
1.08
P/E (TTM)
335.13
P/E (Fwd)
-12.74
EPS (TTM)
$0.08
EPS (Fwd)
$-2.10
ROE
-5.7%
ROA
-5.1%
Cash
$226.6M
Total Debt
$2.5M
Free CF
-$16.6M
52W Change
43.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $226.6M in cash comfortably exceeding the $2.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$16.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -5.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. At over 50x earnings, ASMB carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Assembly Biosciences, Inc. and its sector.